pcDNA-dCas9-p300 Core (C1204R)
(Plasmid
#61361)
-
Purposeencodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; mutation C1204R) driven by CMV promoter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 61361 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerInvitrogen; Life Technologies
- Total vector size (bp) 11475
-
Vector typeMammalian Expression, CRISPR, Synthetic Biology
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameS.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300)
-
SpeciesH. sapiens (human), Synthetic; S. pyogenes
-
Insert Size (bp)6138
-
MutationD10A; H840A in S.pyogenes Cas9; C1204R mutation in p300 Core
-
GenBank IDWP_010922251.1 NP_001420.2
-
Entrez GeneEP300 (a.k.a. KAT3B, MKHK2, RSTS2, p300)
- Promoter CMV
-
Tags
/ Fusion Proteins
- Flag (N terminal on insert)
- SV40 NLS (N terminal on insert)
- SV40 NLS (C terminal on insert)
- HA (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site AscI (not destroyed)
- 3′ cloning site PmeI (not destroyed)
- 5′ sequencing primer CMV F
- 3′ sequencing primer Bgh R (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA-dCas9-p300 Core (C1204R) was a gift from Charles Gersbach (Addgene plasmid # 61361 ; http://n2t.net/addgene:61361 ; RRID:Addgene_61361) -
For your References section:
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6. 10.1038/nbt.3199 PubMed 25849900